China Resources Double-Crane Pharmaceutical Co Ltd (600062) - Net Assets

Latest as of September 2025: CN¥12.16 Billion CNY ≈ $1.78 Billion USD

Based on the latest financial reports, China Resources Double-Crane Pharmaceutical Co Ltd (600062) has net assets worth CN¥12.16 Billion CNY (≈ $1.78 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥17.01 Billion ≈ $2.49 Billion USD) and total liabilities (CN¥4.85 Billion ≈ $710.14 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check China Resources Double-Crane Pharmaceuti (600062) strategic investment index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥12.16 Billion
% of Total Assets	71.48%
Annual Growth Rate	17.2%
5-Year Change	18.5%
10-Year Change	72.71%
Growth Volatility	61.59

China Resources Double-Crane Pharmaceutical Co Ltd - Net Assets Trend (1994–2024)

This chart illustrates how China Resources Double-Crane Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see China Resources Double-Crane Pharmaceuti (600062) market capitalisation.

Annual Net Assets for China Resources Double-Crane Pharmaceutical Co Ltd (1994–2024)

The table below shows the annual net assets of China Resources Double-Crane Pharmaceutical Co Ltd from 1994 to 2024. Also explore 600062 net assets growth trend to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2024-12-31	CN¥11.11 Billion ≈ $1.63 Billion	-5.75%
2023-12-31	CN¥11.79 Billion ≈ $1.73 Billion	+9.88%
2022-12-31	CN¥10.73 Billion ≈ $1.57 Billion	+2.42%
2021-12-31	CN¥10.48 Billion ≈ $1.53 Billion	+11.73%
2020-12-31	CN¥9.38 Billion ≈ $1.37 Billion	+8.07%
2019-12-31	CN¥8.68 Billion ≈ $1.27 Billion	+9.71%
2018-12-31	CN¥7.91 Billion ≈ $1.16 Billion	+0.76%
2017-12-31	CN¥7.85 Billion ≈ $1.15 Billion	+11.51%
2016-12-31	CN¥7.04 Billion ≈ $1.03 Billion	+9.40%
2015-12-31	CN¥6.43 Billion ≈ $941.48 Million	+13.19%
2014-12-31	CN¥5.68 Billion ≈ $831.80 Million	+6.52%
2013-12-31	CN¥5.34 Billion ≈ $780.86 Million	+13.37%
2012-12-31	CN¥4.71 Billion ≈ $688.74 Million	+8.37%
2011-12-31	CN¥4.34 Billion ≈ $635.56 Million	+10.63%
2010-12-31	CN¥3.93 Billion ≈ $574.49 Million	+11.07%
2009-12-31	CN¥3.53 Billion ≈ $517.25 Million	+12.20%
2008-12-31	CN¥3.15 Billion ≈ $461.01 Million	+33.23%
2007-12-31	CN¥2.36 Billion ≈ $346.03 Million	+18.52%
2006-12-31	CN¥2.00 Billion ≈ $291.96 Million	+2.88%
2005-12-31	CN¥1.94 Billion ≈ $283.78 Million	+12.27%
2004-12-31	CN¥1.73 Billion ≈ $252.76 Million	+0.62%
2003-12-31	CN¥1.72 Billion ≈ $251.20 Million	+6.96%
2002-12-31	CN¥1.60 Billion ≈ $234.85 Million	+7.71%
2001-12-31	CN¥1.49 Billion ≈ $218.03 Million	+74.21%
2000-12-31	CN¥855.27 Million ≈ $125.15 Million	+20.25%
1999-12-31	CN¥711.23 Million ≈ $104.08 Million	+31.36%
1998-12-31	CN¥541.45 Million ≈ $79.23 Million	+14.49%
1997-12-31	CN¥472.91 Million ≈ $69.20 Million	+346.93%
1996-12-31	CN¥105.81 Million ≈ $15.48 Million	+2.61%
1995-12-31	CN¥103.12 Million ≈ $15.09 Million	+8.65%
1994-12-31	CN¥94.91 Million ≈ $13.89 Million	--

Equity Component Analysis

This analysis shows how different components contribute to China Resources Double-Crane Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 483497.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥9.24 Billion	88.83%
Common Stock	CN¥1.04 Billion	9.98%
Other Comprehensive Income	CN¥-19.30 Million	-0.19%
Other Components	CN¥143.30 Million	1.38%
Total Equity	CN¥10.41 Billion	100.00%

China Resources Double-Crane Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of China Resources Double-Crane Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Boyd Group Services Inc. NYSE:BGSI	$2.43 Billion
Sociedad Punta del Cobre S.A SN:PUCOBRE	$2.43 Billion
Elmos Semiconductor SE F:ELG	$2.43 Billion
Liberty Live Holdings, Inc. Series A Liberty Live Group Common Stock NASDAQ:LLYVA	$2.43 Billion
KANSAI PAINT SPON.ADR/1/2 F:KAP0	$2.43 Billion
Adaptive Biotechnologies Corp NASDAQ:ADPT	$2.43 Billion
LandBridge Company LLC NYSE:LB	$2.43 Billion
Haemonetics Corporation NYSE:HAE	$2.43 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in China Resources Double-Crane Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 11,090,411,326 to 10,407,864,932, a change of -682,546,394 (-6.2%).
Net income of 1,627,718,410 contributed positively to equity growth.
Dividend payments of 1,479,288,722 reduced retained earnings.
Share repurchases of 5,355,569 reduced equity.
Other comprehensive income decreased equity by 399,345,375.
Other factors decreased equity by 426,275,138.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥1.63 Billion	+15.64%
Dividends Paid	CN¥1.48 Billion	-14.21%
Share Repurchases	CN¥5.36 Million	-0.05%
Other Comprehensive Income	CN¥-399.35 Million	-3.84%
Other Changes	CN¥-426.28 Million	-4.1%
Total Change	CN¥-	-6.15%

Book Value vs Market Value Analysis

This analysis compares China Resources Double-Crane Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.58x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 128.33x to 1.58x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1994-12-31	CN¥0.12	CN¥15.98	x
1995-12-31	CN¥0.14	CN¥15.98	x
1996-12-31	CN¥0.14	CN¥15.98	x
1997-12-31	CN¥0.62	CN¥15.98	x
1998-12-31	CN¥0.70	CN¥15.98	x
1999-12-31	CN¥0.91	CN¥15.98	x
2000-12-31	CN¥1.04	CN¥15.98	x
2001-12-31	CN¥1.68	CN¥15.98	x
2002-12-31	CN¥1.84	CN¥15.98	x
2003-12-31	CN¥1.96	CN¥15.98	x
2004-12-31	CN¥2.02	CN¥15.98	x
2005-12-31	CN¥2.27	CN¥15.98	x
2006-12-31	CN¥2.38	CN¥15.98	x
2007-12-31	CN¥2.88	CN¥15.98	x
2008-12-31	CN¥3.84	CN¥15.98	x
2009-12-31	CN¥4.22	CN¥15.98	x
2010-12-31	CN¥4.69	CN¥15.98	x
2011-12-31	CN¥5.17	CN¥15.98	x
2012-12-31	CN¥5.65	CN¥15.98	x
2013-12-31	CN¥6.48	CN¥15.98	x
2014-12-31	CN¥5.44	CN¥15.98	x
2015-12-31	CN¥5.85	CN¥15.98	x
2016-12-31	CN¥6.41	CN¥15.98	x
2017-12-31	CN¥7.15	CN¥15.98	x
2018-12-31	CN¥7.51	CN¥15.98	x
2019-12-31	CN¥8.25	CN¥15.98	x
2020-12-31	CN¥8.91	CN¥15.98	x
2021-12-31	CN¥9.49	CN¥15.98	x
2022-12-31	CN¥9.68	CN¥15.98	x
2023-12-31	CN¥10.83	CN¥15.98	x
2024-12-31	CN¥10.13	CN¥15.98	x

Capital Efficiency Dashboard

This dashboard shows how efficiently China Resources Double-Crane Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 15.64%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 14.52%
• Asset Turnover: 0.67x
• Equity Multiplier: 1.60x
Recent ROE (15.64%) is above the historical average (14.58%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1994	33.15%	20.07%	1.19x	1.38x	CN¥21.97 Million
1995	42.66%	26.17%	1.27x	1.28x	CN¥33.68 Million
1996	47.88%	24.31%	1.35x	1.46x	CN¥40.08 Million
1997	10.05%	20.12%	0.41x	1.22x	CN¥257.52K
1998	11.40%	17.36%	0.47x	1.39x	CN¥7.48 Million
1999	10.96%	10.49%	0.61x	1.71x	CN¥6.66 Million
2000	13.72%	9.28%	0.79x	1.88x	CN¥29.39 Million
2001	11.85%	6.38%	0.87x	2.14x	CN¥23.74 Million
2002	12.00%	4.57%	1.02x	2.58x	CN¥28.02 Million
2003	4.25%	1.49%	1.00x	2.85x	CN¥-85.82 Million
2004	0.31%	0.11%	1.04x	2.62x	CN¥-149.13 Million
2005	10.73%	4.03%	1.21x	2.21x	CN¥12.70 Million
2006	9.08%	4.07%	1.24x	1.80x	CN¥-16.66 Million
2007	19.91%	9.60%	1.24x	1.67x	CN¥217.83 Million
2008	12.36%	7.69%	1.16x	1.39x	CN¥72.62 Million
2009	13.08%	9.01%	1.07x	1.36x	CN¥106.97 Million
2010	13.46%	9.69%	1.03x	1.35x	CN¥133.78 Million
2011	12.42%	8.35%	1.04x	1.43x	CN¥103.23 Million
2012	13.20%	8.79%	1.07x	1.40x	CN¥149.05 Million
2013	16.33%	12.74%	1.05x	1.22x	CN¥337.42 Million
2014	12.97%	14.29%	0.78x	1.17x	CN¥168.71 Million
2015	10.83%	12.87%	0.66x	1.27x	CN¥50.40 Million
2016	10.68%	13.00%	0.67x	1.23x	CN¥45.59 Million
2017	11.30%	13.12%	0.68x	1.27x	CN¥96.93 Million
2018	12.35%	11.78%	0.80x	1.31x	CN¥184.60 Million
2019	12.27%	11.25%	0.83x	1.31x	CN¥194.87 Million
2020	10.82%	11.82%	0.68x	1.34x	CN¥75.75 Million
2021	9.45%	10.27%	0.67x	1.38x	CN¥-54.86 Million
2022	11.77%	12.26%	0.66x	1.44x	CN¥177.80 Million
2023	15.06%	14.77%	0.73x	1.39x	CN¥561.34 Million
2024	15.64%	14.52%	0.67x	1.60x	CN¥586.93 Million

Industry Comparison

This section compares China Resources Double-Crane Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $2,159,462,338
Average return on equity (ROE) among peers: 8.85%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
China Resources Double-Crane Pharmaceutical Co Ltd (600062)	CN¥12.16 Billion	33.15%	0.40x	$2.43 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$5.88 Billion	7.12%	1.83x	$577.52 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$638.89 Million	0.88%	0.70x	$407.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$793.34 Million	10.94%	0.24x	$4.35 Billion
Livzon Pharmaceutical Group Inc (000513)	$275.56 Million	21.50%	1.16x	$2.29 Billion
Wedge Industrial Co Ltd (000534)	$654.70 Million	1.92%	0.87x	$1.74 Billion
Yunnan Baiyao Group Co Ltd (000538)	$893.64 Million	25.78%	0.79x	$13.25 Billion
Hainan Haiyao Co Ltd (000566)	$1.49 Billion	5.19%	0.85x	$861.90 Million
Tus Pharmaceutical Group Co Ltd (000590)	$347.80 Million	3.58%	0.72x	$308.02 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$869.73 Million	4.99%	1.99x	$964.68 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$9.75 Billion	6.63%	0.12x	$3.04 Billion

About China Resources Double-Crane Pharmaceutical Co Ltd

SHG:600062 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.43 Billion

CN¥16.60 Billion CNY

Market Cap Rank

#5527 Global

#1003 in China

Share Price

CN¥15.98

Change (1 day)

-0.44%

52-Week Range

CN¥15.60 - CN¥19.70

All Time High

CN¥33.06